<DOC>
	<DOCNO>NCT00929188</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness JNJ-42160443 placebo treatment chronic , moderate severe cancer-related pain terminally ill patient diagnosis active cancer .</brief_summary>
	<brief_title>A Study Safety Effectiveness JNJ-42160443 add-on Treatment Patients With Cancer-related Pain</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither physician patient know name assign drug ) study evaluate safety effectiveness JNJ-42160443 compare placebo treatment men woman 18 year age old terminally ill ( ie , patient candidate hospice palliative [ medical care ] care end-of-life management ) moderate severe , chronic , cancer-related pain control standard pain medication diagnosis active cancer . The duration study approximately 62 week ( include screening , 4-week double-blind phase follow 48-week open-label [ study doctor patient know name assign treatment ] extension phase posttreatment phase ) . A single dose JNJ-42160443 matching placebo give ( subcutaneous [ SC ] ) injection skin double-blind treatment period . During open-label period , JNJ-42160443 give every 4 week 48 week .</detailed_description>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Terminally ill cancer patient per judgment investigator ( eg , patient candidate hospice palliative care endoflife management ) ; Diagnosis moderate severe pain directly relate active cancer control standard pain treatment . Planned major surgical procedure doubleblind treatment phase may affect study outcome ; Prior treatment investigational NGF inhibitor therapy ; Known allergy , hypersensitivity , intolerance JNJ42160443 excipients ; Enrolled investigational study within previous 4 week 5 halflives investigational drug ( whichever longer ) , currently enrol another investigational study time screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Moderate severe chronic , cancer-related pain related active cancer</keyword>
	<keyword>Cancer-related pain</keyword>
	<keyword>Moderate severe chronic pain</keyword>
	<keyword>JNJ-42160443</keyword>
</DOC>